DRUG · Mapped RxNorm record
Brentuximab Vedotin
Normalized identity: brentuximab vedotinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
NCT03007030
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedBrentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Brentuximab VedotinDRUG · verified · RxNorm: brentuximab vedotin
Sponsors & collaborators
M.D. Anderson Cancer Centerlead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03007030 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.